S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
NASDAQ:HRTX

Heron Therapeutics - HRTX Stock Forecast, Price & News

$1.73
-0.18 (-9.42%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.72
$1.94
50-Day Range
$1.91
$3.25
52-Week Range
$1.72
$6.38
Volume
2.02 million shs
Average Volume
1.74 million shs
Market Capitalization
$205.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

Heron Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
385.5% Upside
$8.40 Price Target
Short Interest
Bearish
19.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.07mentions of Heron Therapeutics in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

606th out of 995 stocks

Pharmaceutical Preparations Industry

291st out of 482 stocks


HRTX stock logo

About Heron Therapeutics (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Dow futures tick higher, banking crisis weighs
Q4 2022 Heron Therapeutics Inc Earnings Call
Heron Therapeutics's Earnings Outlook
Heron Therapeutics (HRTX) to Release Earnings on Thursday
HRTX Heron Therapeutics, Inc.
HRTX.A - | Stock Price & Latest News | Reuters
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Company Calendar

Last Earnings
3/23/2023
Today
3/27/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
302
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+403.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-220,680,000.00
Net Margins
-169.05%
Pretax Margin
-220.55%

Debt

Sales & Book Value

Annual Sales
$107.67 million
Book Value
$0.76 per share

Miscellaneous

Free Float
112,920,000
Market Cap
$226.49 million
Optionable
Optionable
Beta
0.86

Social Links


Key Executives

  • Barry D. Quart
    Chairman & Chief Executive Officer
  • John W. Poyhonen
    President & Chief Commercial Officer
  • David L. Szekeres
    Chief Operating Officer & Executive Vice President
  • Thomas B. Ottoboni
    Chief Scientific Officer & SVP-Pharmaceutical
  • Chris M. Storgard
    Chief Medical Officer













HRTX Stock - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price targets for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $12.00. On average, they expect the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 385.5% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2023?

Heron Therapeutics' stock was trading at $2.50 at the beginning of 2023. Since then, HRTX stock has decreased by 30.8% and is now trading at $1.73.
View the best growth stocks for 2023 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to the consensus estimate of $27.24 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 2,213.33% and a negative net margin of 169.05%. The firm's revenue was up 44.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Global X Aging Population ETF (AGNG).

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (9.98%), JPMorgan Chase & Co. (5.68%), Palisade Capital Management LLC NJ (3.18%), Palisade Capital Management LP (3.18%), Tang Capital Management LLC (3.16%) and ArrowMark Colorado Holdings LLC (3.00%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $1.73.

How much money does Heron Therapeutics make?

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $205.68 million and generates $107.67 million in revenue each year. The biotechnology company earns $-220,680,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How many employees does Heron Therapeutics have?

The company employs 302 workers across the globe.

Does Heron Therapeutics have any subsidiaries?
The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More
How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.

This page (NASDAQ:HRTX) was last updated on 3/27/2023 by MarketBeat.com Staff